The mutually exclusive mutations between TP53 and CASP8, and co-occurring mutations between TP53 and CDKN2A, further support the genetic basis of tumor metastasis: TP53 mutation disrupts cell cycle checkpoints [58, 59], while CDKN2A loss enhances cell proliferation [60]. Here, CDKN2A is linked to neoplasm.